Reaction

Injection Site Discharge reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,031 reports · 68 co-occurring drugs

As of the last recalculation, Injection Site Discharge appears in 5,031 FAERS reports alongside 68 co-occurring drug terms. The strongest observed disproportionality signal is FREMANEZUMAB-VFRM (PRR 46.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fremanezumab-Vfrm	126	46.5	47.1
Cabotegravir	56	29.0	29.2
Somatropin	327	19.6	19.7
Treprostinil	481	17.4	17.5
Oral Semaglutide	213	12.5	12.5
Risankizumab-Rzaa	200	10.5	10.5
Ofatumumab	80	10.1	10.1
Human Immunoglobulin G	47	9.5	9.5
Tadalafil	171	7.3	7.3
Vedolizumab	137	6.7	6.7
Diphenhydramine Hydrochloride Capsule, Liquid Filled	34	6.6	6.6
Adalimumab	891	6.1	6.1
Alirocumab	34	5.6	5.6
Ambrisentan	162	5.5	5.5
Bimekizumab	28	5.5	5.5
Macitentan	88	5.3	5.3
Adrenalinum	50	5.0	5.0
Cetirizine Hcl	11	5.0	5.0
Sildenafil Citrate	147	4.9	4.9
Sildenafil	67	4.8	4.8
Bosentan	56	4.6	4.6
Asfotase Alfa	11	4.6	4.6
Benralizumab	21	4.4	4.4
Sildenafil Powder,	36	4.2	4.2
Riociguat	29	3.7	3.7
Lidocaine	51	3.6	3.6
Hydroxyzine Hydrochloride	11	3.5	3.5
Hydroxyzine Hydrochloride Oral	11	3.5	3.5
0Xygen	41	3.5	3.5
Oxygen	41	3.5	3.5
Lidicaine	40	3.4	3.4
Burn Relief	40	3.4	3.4
Lidocaine Hydrochloride And Epinephrine	40	3.4	3.4
Teduglutide	11	3.4	3.4
Lidocaine, Menthol	40	3.4	3.4
Epinephrine	52	3.3	3.3
Fluticasone Propionate Nasal	24	3.3	3.3
Lidocaine 4%	42	3.2	3.2
Galcanezumab-Gnlm	24	3.2	3.2
Leuprolide Acetate	58	3.1	3.1
Abaloparatide	22	3.1	3.1
Interferon Beta-1B	14	3.0	3.0
Oxycodone And Acetaminophen Tablets	8	2.8	2.8
Azelastine	12	2.8	2.8
Selexipag	17	2.7	2.7
Glatiramer Acetate	39	2.7	2.7
Buprenorphine	57	2.6	2.6
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	2.4	2.4
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	2.4	2.4
Naltrexone	17	2.3	2.3
Epoprostenol	7	2.2	2.2
Secukinumab	67	1.7	1.7
Paliperidone Palmitate	13	1.7	1.7
Dupilumab	189	1.6	1.6
Guselkumab	14	1.6	1.6
Ixekizumab	14	1.6	1.6
Vibegron	3	1.5	1.5
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	14	1.4	1.4
Emicizumab	4	1.3	1.3
Nemolizumab-Ilto	4	1.3	1.3
Certolizumab Pegol	36	1.3	1.3
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	1.2	1.2
Exenatide	14	1.1	1.1
Sarilumab	7	1.1	1.1
Dulaglutide	20	0.9	0.9
Tirzepatide	36	0.9	0.9
Erenumab-Aooe	12	0.9	0.9
Evolocumab	25	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.